NRX-0492

• Target :

  BTK|||Others|||PROTACs

• Related Pathways :

  Others|||Tyrosine Kinase/Adaptors|||PROTAC|||Angiogenesis

• Bioactivity :

  NRX-0492 is an orally administered compound that efficiently degrades Bruton's tyrosine kinase (BTK) by catalyzing its ubiquitylation and subsequent proteasomal degradation, achieving half-maximal degradation concentrations (DC50) of ?0.2 nM and 90% degradation concentrations (DC90) of ?0.5 nM. Additionally, NRX-0492 suppresses B-cell receptor (BCR) signaling, transcriptional activities, and chemokine production by linking a noncovalent BTK-binding domain to Cereblon, an adaptor protein within the E3 ubiquitin ligase complex [1].

• Smiles :

  O=C1C=2C(C(=O)N1C3C(=O)NC(=O)CC3)=CC=C(C2)N4C[C@H](CN5CCC(CC5)C6=CC=C(NC7=NC(=CN=C7C(N)=O)N8C[C@@H](CCC8)N9CCN(C)C9=O)C=C6)CC4

• Molecular Formula :

  C43H51N11O6

• Molecular Weight :

  817.94

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  2416130-57-7